The association between the preoperative serum levels of lipocalin-2 and matrix metalloproteinase-9 MMP-9 and prognosis of breast cancerReport as inadecuate




The association between the preoperative serum levels of lipocalin-2 and matrix metalloproteinase-9 MMP-9 and prognosis of breast cancer - Download this document for free, or read online. Document in PDF available to download.

BMC Cancer

, 12:193

First Online: 28 May 2012Received: 21 August 2011Accepted: 14 May 2012DOI: 10.1186-1471-2407-12-193

Cite this article as: Sung, H., Choi, JY., Lee, SA. et al. BMC Cancer 2012 12: 193. doi:10.1186-1471-2407-12-193

Abstract

BackgroundAlthough a number of experimental studies have suggested the role of lipocalin-2 LCN2 and matrix metalloproteinase-9 MMP-9 in breast cancer progression, limited numbers of epidemiological studies have examined the relationship between the levels of lipocalin-2 and MMP-9 and breast cancer survival.

MethodsPreoperative serum levels of lipocalin-2 and MMP-9 were measured in 303 breast cancer patients and 74 healthy controls recruited between 2004 and 2007. We examined the association between lipocalin-2 and MMP-9 levels and disease-free survival DFS using Cox proportional hazard regression model.

ResultsThe serum levels of lipocalin-2 and MMP-9 were not significantly different between patients and controls P > 0.05. Elevated lipocalin-2 and MMP-9 levels were associated with reduced DFS of breast cancer Ptrend = 0.029 and Ptrend = 0.063, respectively. When lipocalin-2 and MMP-9 levels were categorized based on the combined risk score, patients with higher levels of both lipocalin-2 and MMP-9 exhibited poor DFS compared to patients with lower levels Ptrend = 0.004. Furthermore, these effects were profound in patients with BMI less than 25 kg-m adjusted hazard ratio aHR, 3.17; 95% confidence intervals CI, 1.66-6.06, Ptrend < 0.001 or lymph-node negative breast cancer aHR, 5.36; 95% CI, 2.18-13.2, Ptrend < 0.001.

ConclusionsOur study suggests that the elevated levels of lipocalin-2 and MMP-9 are associated with reduced breast cancer survival, particularly in patients with lower BMI and lymph-node negative breast cancers.

AbbreviationsaHRAdjusted hazard ratio

BMIBody mass index

CIConfidence intervals

DFSDisease-free survival

EMTEpithelial-mesenchymal transition

EREstrogen receptor

HRHazard ratio

LCN2Lipocalin-2

MDDMinimum detectable dose

LNLymph-node negative

LN +Lymph-node positive

MMP-9Matrix metalloproteinase-9

NGALNeutrophil gelatinase-associated lipocalin

PRProgesterone receptor

SDStandard deviations.

Electronic supplementary materialThe online version of this article doi:10.1186-1471-2407-12-193 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Hyuna Sung - Ji-Yeob Choi - Sang-Ah Lee - Kyoung-Mu Lee - Sohee Han - Sujee Jeon - Minkyo Song - Yunhee Lee - Sue K Park

Source: https://link.springer.com/







Related documents